secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2023-08-15T23:59:59+00:00
Accession:  0001213900-23-067474
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Q3 net loss $8.5M; FDA CRL for LYMPHIR (no safety/efficacy issues); $33.3M cash runway to Aug 2024
--------------------------------------------------------------------------------

- Net loss of $8.5M ($0.06 EPS) for Q3 2023; nine-month loss $22.6M ($0.15 EPS).
- Cash $33.3M, runway through Aug 2024; $13.8M net from May 2023 $1.20/share offering.
- Mino-Lok Phase 3 trial achieved 92 required events (pending confirmation); Halo-Lido Phase 2b topline positive.
- LYMPHIR received FDA CRL on July 28; no clinical safety/efficacy issues; planning resubmission.
- R&D expenses $3.8M (down from $4.9M); G&A $3.7M (up from $3.0M) due to pre-launch activities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390023067474/0001213900-23-067474-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390023067474/ea183558-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-067474

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer